Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 172

1.

Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across Côte d’Ivore

Konaté A, Barro-Kiki PCM, Angora KE, Bédia-Tanoh AV, Djohan V, Kassi KF, Vanga-Bosson H, Miézan AJS, Assi SB, Menan EIH, Yavo W.

Ann Parasitol. 2018;64(1):49–57. doi: 10.17420/ap6401.132.

2.

Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA).

Ampadu HH, Dodoo ANO, Bosomprah S, Akakpo S, Hugo P, Gardarsdottir H, Leufkens HGM, Kajungu D, Asante KP.

Drug Saf. 2018 Sep;41(9):871-880. doi: 10.1007/s40264-018-0667-x.

3.

Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.

West African Network for Clinical Trials of Antimalarial Drugs (WANECAM).

Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29.

4.

Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda.

Baraka V, Mavoko HM, Nabasumba C, Francis F, Lutumba P, Alifrangis M, Van Geertruyden JP.

PLoS One. 2018 Feb 1;13(2):e0191922. doi: 10.1371/journal.pone.0191922. eCollection 2018.

5.

Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia.

Medzihradsky OF, Kleinschmidt I, Mumbengegwi D, Roberts KW, McCreesh P, Dufour MK, Uusiku P, Katokele S, Bennett A, Smith J, Sturrock H, Prach LM, Ntuku H, Tambo M, Didier B, Greenhouse B, Gani Z, Aerts A, Gosling R, Hsiang MS.

BMJ Open. 2018 Jan 27;8(1):e019294. doi: 10.1136/bmjopen-2017-019294.

6.

Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.

Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gonçalves BP, Affara M, Ouédraogo A, Bougouma EC, Sanou GS, Nébié I, Bradley J, Lanke KHW, Niemi M, Sirima SB, d'Alessandro U, Bousema T, Drakeley C.

PLoS One. 2018 Jan 11;13(1):e0190272. doi: 10.1371/journal.pone.0190272. eCollection 2018.

7.

Intravenous artesunate plus Artemisnin based Combination Therapy (ACT) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial.

Byakika-Kibwika P, Achan J, Lamorde M, Karera-Gonahasa C, Kiragga AN, Mayanja-Kizza H, Kiwanuka N, Nsobya S, Talisuna AO, Merry C.

BMC Infect Dis. 2017 Dec 28;17(1):794. doi: 10.1186/s12879-017-2924-5.

8.

Cost-effectiveness analysis of introducing malaria diagnostic testing in drug shops: A cluster-randomised trial in Uganda.

Hansen KS, Clarke SE, Lal S, Magnussen P, Mbonye AK.

PLoS One. 2017 Dec 15;12(12):e0189758. doi: 10.1371/journal.pone.0189758. eCollection 2017.

9.

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.

Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, Euswas A, Ittiverakul M, Buathong N, Sriwichai S, Miller RS, Ohrt C.

PLoS One. 2017 Nov 9;12(11):e0187376. doi: 10.1371/journal.pone.0187376. eCollection 2017.

11.

Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa.

Toure OA, Mwapasa V, Sagara I, Gaye O, Thompson R, Maheshwar AV, Mishra P, Behra N, Tshefu AK, Das RR, Anvikar AR, Sharma P, Roy A, Sharma SK, Nasa A, Jalali RK, Valecha N; Arterolane Maleate-Piperaquine Phosphate (AM-PQP) Study Team.

Clin Infect Dis. 2017 Oct 30;65(10):1711-1720. doi: 10.1093/cid/cix617.

PMID:
29020247
12.

A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria.

Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, Tinto H, Bassat Q, Issifou S, Adamy M, Demarest H, Duparc S, Leroy D, Laurijssens BE, Biguenet S, Kibuuka A, Tshefu AK, Smith M, Foster C, Leipoldt I, Kremsner PG, Phuc BQ, Ouedraogo A, Ramharter M; OZ-Piperaquine Study Group.

BMC Med. 2017 Oct 9;15(1):181. doi: 10.1186/s12916-017-0940-3.

13.

A Molecular Assay to Quantify Male and Female Plasmodium falciparum Gametocytes: Results From 2 Randomized Controlled Trials Using Primaquine for Gametocyte Clearance.

Stone W, Sawa P, Lanke K, Rijpma S, Oriango R, Nyaurah M, Osodo P, Osoti V, Mahamar A, Diawara H, Woestenenk R, Graumans W, van de Vegte-Bolmer M, Bradley J, Chen I, Brown J, Siciliano G, Alano P, Gosling R, Dicko A, Drakeley C, Bousema T.

J Infect Dis. 2017 Aug 15;216(4):457-467. doi: 10.1093/infdis/jix237.

14.

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial.

Koita OA, Sangaré L, Miller HD, Sissako A, Coulibaly M, Thompson TA, Fongoro S, Diarra Y, Ba M, Maiga A, Diallo B, Mushatt DM, Mather FJ, Shaffer JG, Anwar AH, Krogstad DJ.

Lancet Infect Dis. 2017 Dec;17(12):1266-1275. doi: 10.1016/S1473-3099(17)30365-1. Epub 2017 Sep 12.

15.

Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine.

Fanello C, Onyamboko M, Lee SJ, Woodrow C, Setaphan S, Chotivanich K, Buffet P, Jauréguiberry S, Rockett K, Stepniewska K, Day NPJ, White NJ, Dondorp AM.

BMC Infect Dis. 2017 Aug 17;17(1):575. doi: 10.1186/s12879-017-2678-0.

16.

Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.

Wampfler R, Hofmann NE, Karl S, Betuela I, Kinboro B, Lorry L, Silkey M, Robinson LJ, Mueller I, Felger I.

PLoS Negl Trop Dis. 2017 Jul 21;11(7):e0005753. doi: 10.1371/journal.pntd.0005753. eCollection 2017 Jul.

17.

Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria.

Supan C, Mombo-Ngoma G, Kombila M, Ospina Salazar CL, Held J, Lell B, Cantalloube C, Djeriou E, Ogutu B, Waitumbi J, Otsula N, Apollo D, Polhemus ME, Kremsner PG, Walsh DS.

Am J Trop Med Hyg. 2017 Aug;97(2):514-525. doi: 10.4269/ajtmh.16-0731. Epub 2017 Jul 19.

18.

Molecular Markers for Sensitive Detection of Plasmodium falciparum Asexual Stage Parasites and their Application in a Malaria Clinical Trial.

Tadesse FG, Lanke K, Nebie I, Schildkraut JA, Gonçalves BP, Tiono AB, Sauerwein R, Drakeley C, Bousema T, Rijpma SR.

Am J Trop Med Hyg. 2017 Jul;97(1):188-198. doi: 10.4269/ajtmh.16-0893.

19.

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.

Chotsiri P, Wattanakul T, Hoglund RM, Hanboonkunupakarn B, Pukrittayakamee S, Blessborn D, Jittamala P, White NJ, Day NPJ, Tarning J.

Br J Clin Pharmacol. 2017 Dec;83(12):2752-2766. doi: 10.1111/bcp.13372. Epub 2017 Aug 16.

20.

Use of malaria rapid diagnostic tests by community health workers in Afghanistan: cluster randomised trial.

Leslie T, Rowland M, Mikhail A, Cundill B, Willey B, Alokozai A, Mayan I, Hasanzai A, Baktash SH, Mohammed N, Wood M, Rahimi HU, Laurent B, Buhler C, Whitty CJM.

BMC Med. 2017 Jul 7;15(1):124. doi: 10.1186/s12916-017-0891-8.

Supplemental Content

Loading ...
Support Center